ArticlePhytotherapy research : PTR2025
Phillygenin Improves the Focal Adhesion Kinase/Glycogen Synthase Kinase 3β/β-Catenin Axis to Promote Mesenchymal Stem Cell Osteogenic Differentiation.
Article in Phytotherapy research : PTR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phillygenin Improves the Focal Adhesion Kinase/Glycogen Synthase Kinase 3β/β-Catenin Axis to Promote Mesenchymal Stem Cell Osteogenic Differentiation.Phytotherapy research : PTR · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Forsythiae Fructus, a traditional herb known for its anti-inflammatory and antioxidant properties, has demonstrated inconclusive effects on bone metabolism in prior studies. The aim of this study is to investigate whether phillygenin (PHI), an active component of Forsythiae Fructus, promotes osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) by modulating the FAK/GSK-3β/β-catenin signaling axis. Experimental procedure: In vivo, an ovariectomized (OVX) mouse model was employed to mimic postmenopausal bone loss. In vitro, osteoclastogenesis was evaluated using tartarate-resistant acid phosphatase (TRAP) enzymatic assays, while osteogenic differentiation of BMSCs was assessed through alkaline phosphatase (ALP) and alizarin red S (ARS) staining. Cell proliferation and viability were examined using the CCK-8 assay. Osteogenic markers, including ALP, RUNX2, osteopontin (OPN), as well as signaling proteins, such as phosphorylated FAK at Y397 (pFAKY397), phosphorylated glycogen synthase kinase-3 beta (pGSK-3β), and β-catenin, were analyzed by western blot and immunofluorescence analyses. Specific inhibitors of the FAK and β-catenin (Y15 and XAV-939) were employed for mechanistic validation. PHI treatment significantly decreased the number and size of osteoclasts in a dose-dependent way. In OVX mice, PHI preserved trabecular microarchitecture, increased bone mineral density, and inhibited osteoclast formation dose-dependently. Low doses of PHI significantly promoted osteogenic differentiation and mineralization of BMSCs without affecting cell proliferation and viability. Mechanistically, PHI upregulated the expression of pFAKY397, pGSK-3β, and β-catenin. Inhibition of the pathway, achieved through the use of Y15 and XAV-939, attenuated PHI-induced osteogenesis. These findings indicate that PHI enhances BMSCs osteogenesis via the FAK/GSK-3β/β-catenin axis, thereby restoring bone metabolic balance. The results highlight PHI's dual regulatory potential in the management of bone disorders, particularly, estrogen deficiency-related osteoporosis, and suggest its potential applications in the therapeutic intervention of bone diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.